News and Trends 29 May 2020 Argenx Follows up Phase III Success with Giant €785M Global Offering The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global share offering. Argenx’s fundraise swiftly follows the announcement of phase III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. […] May 29, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2020 Argenx’s Rare Disease Treatment Strikes Gold in Phase III The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved motor symptoms of the autoimmune disease myasthenia gravis in a phase III trial. The phase III trial tested the effect of efgartigimod in 167 patients with generalized myasthenia gravis. In this incurable chronic condition, the […] May 26, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 21 May 2020 What 2019 Can Teach About European Biotech Investments Going Forward Following 2018’s bumper harvest for equity funding in European biotech, 2019 proved even more lucrative, particularly for private biotech companies. What are the biggest investment lessons learned from 2019, and how could Covid-19 change the dynamic in 2020? With the coronavirus pandemic thrusting global industry sectors into chaos, investors and entrepreneurs need to understand the […] May 21, 2020 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2020 Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […] May 19, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2020 Gamida Cell’s Bone Marrow Transplant Cuts Treatment Time in Phase III A rapid-acting bone marrow transplant developed by the Israeli biotech Gamida Cell was engrafted in blood cancer patients 10 days faster than standard umbilical cord blood transplants in a phase III trial. The trial recruited 125 blood cancer patients in more than 50 clinical centers globally. One group received a standard transplant of donor umbilical […] May 12, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 1 May 2020 Belgian Company Harnesses Lab-on-a-Chip Technology to Diagnose Disease The Belgian startup miDiagnostics is developing technology to diagnose diseases quickly, accurately, and at the point-of-care using a silicon lab-on-a-chip and nanoscale-precision microfluidics. Having good diagnostics in place can save lives. This principle is especially true in times of crisis, such as the current coronavirus pandemic. However, producing good diagnostics isn’t a simple task. In […] May 1, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2020 Update: Kurma Partners’ Third Biofund Closes at €160M Update (30/04/2020): The French VC firm Kurma Partners has completed the final closing of its third therapeutic fund, exceeding its initial target of €150M. The final closing of Kurma Biofund III was supported by Bpifrance, the European Investment Fund, Idinvest Partners, the Pasteur Institute, the German public development bank NRW.BANK, and Servier Laboratories. Kurma managed […] April 30, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2020 First Volunteers Dosed with European Coronavirus Vaccine The first European vaccine for coronavirus disease to enter clinical trials has been administered to UK volunteers in a project led by the University of Oxford. One volunteer was injected with the coronavirus vaccine and another with a control vaccine yesterday in a phase I trial that aims to recruit over 1,000 participants. The trial […] April 24, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2020 Sofinnova Invests €20M in Three Italian Rare Disease Biotechs The French VC firm Sofinnova Partners has invested €20M in three Italian biotech companies via its Telethon Fund, which focuses on firms developing treatments for rare diseases. The deals by the Sofinnova Telethon Fund were made over the last several months. The companies the Fund invested in — Genespire, Epsilen Bio, and PinCell — are […] April 23, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 17 Apr 2020 Amphista Therapeutics Is Silencing Disease Proteins to Treat Cancer Amphista Therapeutics, based in Glasgow, Scotland, is the latest company to develop drugs called PROTACs, which are designed to make the cell degrade harmful proteins to treat cancer. Small molecule drugs have shown incredible potential for the treatment of cancer by blocking harmful proteins in the cell. However, many promising protein targets for cancer treatments […] April 17, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2020 Irish Biotech Raises €18M to Develop Non-Viral Cell Therapy Technology The Irish company Avectas has closed a Series C round to develop cell therapies that don’t need viral vectors — a common bottleneck in cell therapy manufacturing. The fundraise of approximately €18M brings Avectas’ total equity funding to around €37M. The round was led by the company’s current shareholders, which include the serial life sciences […] April 16, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Apr 2020 Healx Deploys AI Drug Discovery Technology Against Rare Nerve Disease The AI-driven drug repurposing company Healx has teamed up with the global Children’s Tumor Foundation (CTF) to develop new treatments for the genetic disease neurofibromatosis type 1, right after the FDA approved the first-ever drug for the condition. In the collaboration, the UK biotech will use its AI-driven pharmacology expertise to speed a candidate drug […] April 15, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email